- Home
- ROIV vs FRHC Comparison
ROIV vs FRHC Comparison
Compare ROIV & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- FRHC
- Stock Information
- Founded
- ROIV 2014
- FRHC N/A
- Country
- ROIV United Kingdom
- FRHC United States
- Employees
- ROIV N/A
- FRHC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- FRHC Investment Bankers/Brokers/Service
- Sector
- ROIV Health Care
- FRHC Finance
- Exchange
- ROIV Nasdaq
- FRHC Nasdaq
- Market Cap
- ROIV 8.6B
- FRHC 10.5B
- IPO Year
- ROIV N/A
- FRHC N/A
- Fundamental
- Price
- ROIV $13.95
- FRHC $164.91
- Analyst Decision
- ROIV Strong Buy
- FRHC
- Analyst Count
- ROIV 4
- FRHC 0
- Target Price
- ROIV $15.50
- FRHC N/A
- AVG Volume (30 Days)
- ROIV 6.7M
- FRHC 100.0K
- Earning Date
- ROIV 11-11-2025
- FRHC 11-07-2025
- Dividend Yield
- ROIV N/A
- FRHC N/A
- EPS Growth
- ROIV N/A
- FRHC N/A
- EPS
- ROIV N/A
- FRHC 1.33
- Revenue
- ROIV $23,233,000.00
- FRHC $1,594,662,000.00
- Revenue This Year
- ROIV N/A
- FRHC N/A
- Revenue Next Year
- ROIV $281.14
- FRHC N/A
- P/E Ratio
- ROIV N/A
- FRHC $123.60
- Revenue Growth
- ROIV N/A
- FRHC 33.74
- 52 Week Low
- ROIV $8.73
- FRHC $92.88
- 52 Week High
- ROIV $14.48
- FRHC $194.01
- Technical
- Relative Strength Index (RSI)
- ROIV 73.22
- FRHC 43.96
- Support Level
- ROIV $11.85
- FRHC $160.07
- Resistance Level
- ROIV $14.48
- FRHC $168.75
- Average True Range (ATR)
- ROIV 0.42
- FRHC 6.15
- MACD
- ROIV 0.19
- FRHC -1.17
- Stochastic Oscillator
- ROIV 81.61
- FRHC 22.20
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.